

Vivian W. Doelling, Ph.D.

Areas of Expertise: Veterinary and human vaccines; R&D, Product Development, QC testing, Process transferal, Business development

Phone Number: 919-971-9287(cell)

Email address: vivian.doelling@scynexis.com

Dr. Doelling has 25 years experience in starting and managing biological research and development operations for therapeutic proteins and vaccines for human and animal use.

She is currently Vice-President, Animal Health for SCYNEXIS, Inc. based in RTP, NC. Previously, Dr. Doelling was the Biological technical lead at Integrated Laboratory Systems, RTP, for the NTP Interagency for the Evaluation of Alternative Toxicological Methods (NICEATM). Dr. Doelling worked as an Independent consultant for the biotechnology and animal health industries with work concentrated in product development, technology assessment, IP portfolio management, licensing, commercialization and strategic planning. She was formerly VP of R&D for Embrex, Inc., RTP and then Director, R&D upon Pfizer Animal Health's acquisition of Embrex in 2007. Dr. Doelling was responsible for all aspects of vaccine and biological product development including discovery, development, analytical, regulatory and clinical evaluation. She led the multifunctional team in obtaining Embrex's first USDA approved vaccine license and co-managed the design and development of a \$20M biological manufacturing facility including facilitating the process transfer to the manufacturing site. Dr. Doelling functioned as site head for all Animal Welfare, AAALAC and IACUC activities. She was a member of the Pfizer Animal Health and Pfizer Global Manufacturing RTP teams, participating in key strategy sessions for technology and commercial expansion. She worked closely with Global Alliances and Business Development to assess IP, research and business opportunities with universities, consortiums and small companies. Prior to this, Dr. Doelling was a Group Leader in Biotechnology Fermentation Development for American Cyanamid Company (now Pfizer) in New York.

Dr. Doelling currently serves on the Industry Advisory Board for the Master's of Microbial Biotechnology (MMB) program at North Carolina State University and as an Executive Council member of the North Carolina One Health Collaborative. She is co-inventor on 6 patents and author on 18 publications and over 50 abstracts. She received her Ph.D., in biochemistry from Purdue University.